ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/066/ERR12644966/ERR12644966.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/074/ERR12644974/ERR12644974.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/075/ERR12644975/ERR12644975.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/063/ERR12644963/ERR12644963.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/068/ERR12644968/ERR12644968.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/064/ERR12644964/ERR12644964.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/061/ERR12644961/ERR12644961.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/070/ERR12644970/ERR12644970.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/072/ERR12644972/ERR12644972.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/062/ERR12644962/ERR12644962.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/073/ERR12644973/ERR12644973.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/059/ERR12644959/ERR12644959.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/071/ERR12644971/ERR12644971.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/060/ERR12644960/ERR12644960.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/069/ERR12644969/ERR12644969.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/065/ERR12644965/ERR12644965.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR126/067/ERR12644967/ERR12644967.fastq.gzprimaryOK200GenomicsEuropean Bioinformatics InstituteInstituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spainhttps://www.ebi.ac.uk/ena/browser/view/PRJEB72409ArrayExpressHere we explore the striatum transcriptomic effects of alpha-synuclein administration in mice as model of Parkinson´s disease. Moreover, we also explore the neuroprotective effect of cannabonoid-based druga (VCE-003.2) as a potential neuroportective agent in Parkinson´s diseaseENAfalseInvestigation in the cannabigerol derivative VCE-003.2 as a disease- modifying agent in a mouse model of experimental synucleinopathyInvestigation in the cannabigerol derivative VCE-003.2 as a disease- modifying agent in a mouse model of experimental synucleinopathy2024-11-302024-11-30PRJEB72409